- Home
- BBT vs IMCR Comparison
BBT vs IMCR Comparison
Compare BBT & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBT
- IMCR
- Stock Information
- Founded
- BBT 1846
- IMCR 2008
- Country
- BBT United States
- IMCR United Kingdom
- Employees
- BBT N/A
- IMCR N/A
- Industry
- BBT Banks
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BBT Finance
- IMCR Health Care
- Exchange
- BBT Nasdaq
- IMCR Nasdaq
- Market Cap
- BBT 2.2B
- IMCR 1.8B
- IPO Year
- BBT N/A
- IMCR 2021
- Fundamental
- Price
- BBT N/A
- IMCR $34.42
- Analyst Decision
- BBT Hold
- IMCR Buy
- Analyst Count
- BBT 1
- IMCR 8
- Target Price
- BBT $33.00
- IMCR $57.00
- AVG Volume (30 Days)
- BBT 537.9K
- IMCR 275.9K
- Earning Date
- BBT 11-08-2025
- IMCR 11-05-2025
- Dividend Yield
- BBT 5.04%
- IMCR N/A
- EPS Growth
- BBT 2.47
- IMCR N/A
- EPS
- BBT 2.10
- IMCR N/A
- Revenue
- BBT $345,393,000.00
- IMCR $356,145,000.00
- Revenue This Year
- BBT $47.36
- IMCR $31.83
- Revenue Next Year
- BBT $79.15
- IMCR $8.50
- P/E Ratio
- BBT $12.18
- IMCR N/A
- Revenue Growth
- BBT 2.90
- IMCR 26.78
- 52 Week Low
- BBT $22.27
- IMCR $23.15
- 52 Week High
- BBT $32.36
- IMCR $39.33
- Technical
- Relative Strength Index (RSI)
- BBT N/A
- IMCR 50.65
- Support Level
- BBT N/A
- IMCR $35.33
- Resistance Level
- BBT N/A
- IMCR $36.76
- Average True Range (ATR)
- BBT 0.00
- IMCR 1.36
- MACD
- BBT 0.00
- IMCR 0.16
- Stochastic Oscillator
- BBT 0.00
- IMCR 40.47
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.